Clinical and Translational Medicine (Dec 2020)
MAFG‐AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma
- Mengqing Xiao,
- Jianye Liu,
- Liang Xiang,
- Kai Zhao,
- Dong He,
- Qinghai Zeng,
- Qun Zhang,
- Dan Xie,
- Minhua Deng,
- Yuxing Zhu,
- Yeyu Zhang,
- Yan Liu,
- Hao Bo,
- Xiaoming Liu,
- Xingyu Chen,
- Lian Gong,
- Ying Bao,
- Yi Hu,
- Yaxin Cheng,
- Liping Deng,
- Rongrong Zhu,
- Xiaowei Xing,
- Ming Zhou,
- Wei Xiong,
- Yanhong Zhou,
- Jianda Zhou,
- Xiaohui Li,
- Ke Cao
Affiliations
- Mengqing Xiao
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Jianye Liu
- Department of Urology Third Xiangya Hospital of Central South University Changsha China
- Liang Xiang
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Kai Zhao
- Department of Hematology Third Xiangya Hospital of Central South University Changsha China
- Dong He
- Department of Respiratory The Second People's Hospital of Hunan Province Changsha China
- Qinghai Zeng
- Department of Dermatology Third Xiangya Hospital of Central South University Changsha China
- Qun Zhang
- Department of Radiotherapy The First Affiliated Hospital of Sun Yat‐sen University Guangzhou China
- Dan Xie
- Department of Pathology Sun Yat‐sen University Cancer Center Guangzhou China
- Minhua Deng
- Department of Urology Sun Yat‐sen University Cancer Center Guangzhou China
- Yuxing Zhu
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Yeyu Zhang
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Yan Liu
- Department of Plastic Surgery Third Xiangya Hospital of Central South University Changsha China
- Hao Bo
- Institute of Reproductive and Stem Cell Engineering Central South University Changsha China
- Xiaoming Liu
- Department of Gastroenterology Third Xiangya Hospital of Central South University Changsha China
- Xingyu Chen
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Lian Gong
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Ying Bao
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Yi Hu
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Yaxin Cheng
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Liping Deng
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Rongrong Zhu
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- Xiaowei Xing
- Center for Medical Experiments Third Xiangya Hospital of Central South University Changsha China
- Ming Zhou
- Cancer Research Institute and Key Laboratory of Carcinogenesis of the Chinese, Ministry of Health Central South University Changsha China
- Wei Xiong
- Cancer Research Institute and Key Laboratory of Carcinogenesis of the Chinese, Ministry of Health Central South University Changsha China
- Yanhong Zhou
- Cancer Research Institute and Key Laboratory of Carcinogenesis of the Chinese, Ministry of Health Central South University Changsha China
- Jianda Zhou
- Department of Plastic Surgery Third Xiangya Hospital of Central South University Changsha China
- Xiaohui Li
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples Changsha China
- Ke Cao
- Department of Oncology Third Xiangya Hospital of Central South University Changsha China
- DOI
- https://doi.org/10.1002/ctm2.241
- Journal volume & issue
-
Vol. 10,
no. 8
pp. n/a – n/a
Abstract
Abstract Long noncoding RNAs (lncRNAs) play a crucial role in progression of bladder urothelial carcinoma (BUC). However, the molecular mechanisms behind this role have not been elucidated yet. Here, we found that the lncRNA MAFG‐AS1, which is highly expressed in BUC, is correlated with aggressive characteristics and poor prognosis of BUC. We demonstrate that MAFG‐AS1 can promote BUC proliferation, invasion, metastasis, and epithelial‐mesenchymal transition in vitro and in vivo. Mechanistically, MAFG‐AS1 direct binding to Hu antigen R (HuR) could recruit ubiquitin‐specific proteinase 5 (USP5) to prevent HuR from degrading by ubiquitination. We further demonstrate that overexpression of MAFG‐AS1 can upregulate the expression of polypyrimidine tract‐binding protein 1 (PTBP1) through promoting its stability mediated by bound HuR. In conclusion, these findings indicate that MAFG‐AS1 promotes the progression of BUC via regulation of the HUR/PTBP1 axis. Targeting MAFG‐AS1 may provide a novel strategy for individualized therapy and a potential biomarker for prognosis of BUC.
Keywords
